Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3818 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Genzyme says one dose Synvisc best for arthritis

The preliminary research indicates that patients achieved a statistically significant improvement in pain from osteoarthritis of the knee over 26 weeks compared with those using placebo. Currently Synvisc

GSK says bladder drug is effective

A secondary endpoint from this study demonstrated that patients taking VESIcare experienced a statistically significant increase in warning time compared with patients taking placebo. VESIcare is the first

Enzo Biochem patent suit goes ahead

Specifically, the court has denied petitions requesting appeal from Applera concerning six Enzo patents asserted against Applera and Tropix, thus allowing Enzo’s infringement case to go forward. The

Actavis to buy generic company Abrika

Actavis believes the deal will leverage its position in the US market. The agreement will concentrate on controlled release products (CR). CR versions of drugs are useful because

Ligand platelet drug advances to phase I

The drug specifically mimics the activity of thrombopoietin (TPO), the key hematopoietic growth factor responsible for platelet production. There are currently no approved TPO molecules available but there